Market Cap
$14.1B
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
$290.19 ▲ +1.17%
Prev close $286.83Market cap$14.1B
ConsensusBuy
12-mo target$305.00 (+5.1%)
▲ Bullish
Analyst conviction 7/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10)35 New Institutional Positions15 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on CRL right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (74%)
Inst. Holders
50 funds
Inst. Value
$10.5B
Inst. Activity
35 buys / 15 sells
Insider Activity
$0.00 buy / $42.6M sell
Insider Net $
-$42.6M
Social Sentiment
63° Warm
SEC Reports
8
Price chart 30d -1.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 24, 2026 short_volume
Aug 28, 2026 SEC Short Volume: CRL — 62.2% short (0.4M / 0.6M)
Short: 383,215 | Exempt: 0 | TRF Vol: 616,224 | Short Ratio: 62.2% | Off-exchange volume (dark pool
Two CRL insiders sold a total of ~$763K in open-market shares over the past week, while Director James C. Foster exercis
CLUSTER — Impact 3/10
Aug 25, 2026 Insider
FOSTER JAMES C sold 33,561 shares
Director @ $300.00 ($10.1M)
Aug 25, 2026 Insider
FOSTER JAMES C acquired via exercise 21,132 shares
Director @ $194.12 ($4.1M)
Aug 25, 2026 Insider
Aug 21, 2026 SEC FOSTER JAMES C acquired via exercise 12,429 shares
Director @ $208.44 ($2.6M)
Three CRL insiders, including CEO Birgit Girshick, sold a total of ~$3.0M in shares over a 7-day window. The CEO's $1.82
CLUSTER — Impact 3/10
A cluster of insider selling at Charles River Laboratories (CRL) totaling $10.21M occurred within 9 days of the Q2 2026
CLUSTER — Impact 3/10
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — ADD
639,803 shares ($145.1M)
Analyst ratings buy % +15.6%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
74% rate it Buy or better · 23 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 28, 2026 | Jefferies | MAINTAIN | Buy | 53% |
| Sep 25, 2026 | Deutsche Bank | MAINTAIN | Buy | 58% |
| Sep 25, 2026 | TD Cowen | MAINTAIN | Buy | 56% |
| Sep 25, 2026 | Evercore ISI Group | MAINTAIN | Outperform | 59% |
| Sep 25, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Sep 25, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Sep 25, 2026 | Mizuho | MAINTAIN | Neutral | 52% |
| Sep 25, 2026 | Baird | MAINTAIN | Outperform | 54% |
| Sep 11, 2026 | Evercore ISI Group | MAINTAIN | Outperform | 59% |
| Aug 10, 2026 | TD Cowen | MAINTAIN | Buy | 56% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 11 | 6 | 0 | 0 | 74% | |
| Aug 1, 2026 | 5 | 10 | 7 | 0 | 0 | 68% | |
| Jul 1, 2026 | 6 | 10 | 7 | 0 | 0 | 70% | |
| Jun 1, 2026 | 7 | 9 | 8 | 0 | 0 | 67% | |
| May 1, 2026 | 7 | 8 | 9 | 0 | 0 | 63% | |
| Apr 1, 2026 | 7 | 7 | 9 | 0 | 0 | 61% | |
| Mar 1, 2026 | 7 | 7 | 9 | 0 | 0 | 61% | |
| Feb 1, 2026 | 7 | 7 | 9 | 0 | 0 | 61% |
Price targets
Where 15 covering analysts think CRL trades over the next 12 months.
$305.00 +5.1% upside Buy
Current$290.19 Low$145.00 Median$322.00 High$357.00 15 analysts
$145.00$357.00
Analyst rating Buy· 1.7/5 as of Oct 2, 2026
Social media sentiment mood +50.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
63°
Warm
BearishNeutralBullish
Recent posts
NRx Pharmaceuticals (NRXP) - Outstanding DARPA-funding PR published this morning PLUS status update to September Catalysts post from a month ago. The positive catalysts are mounting!
▲ 1 · 💬 1· ⚡ 0.5
NRx Pharmaceuticals (NRXP) - Two September Catalysts Upon Us
▲ 1 · 💬 1· ⚡ 0.5
ZYME - FDA decision on Aug 25: opportunity or already priced in?
▲ 1 · 💬 4· ⚡ 0.5
ZYME - FDA decision on Aug 25: opportunity or already priced in?
▲ 1 · 💬 0· ⚡ 0.5
Turned $10k into $29k in 3 trades. Trade #004: $29k ALL-IN on $RARE ahead of the FDA decision
▲ 1 · 💬 6· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 1 bullish, 1 bearish, 1 mixed, 5 neutral · avg impact 4.4/10.
NEUTRALCLUSTER3/10
Two CRL insiders sold a total of ~$763K in open-market shares over the past week, while Director Jam
Aug 28, 2026
NEUTRALCLUSTER3/10
Three CRL insiders, including CEO Birgit Girshick, sold a total of ~$3.0M in shares over a 7-day win
Aug 21, 2026
NEUTRALCLUSTER3/10
A cluster of insider selling at Charles River Laboratories (CRL) totaling $10.21M occurred within 9
Aug 14, 2026
NEUTRALCLUSTER3/10
A cluster of insider selling at Charles River Laboratories (CRL) totaling $10.5M in open-market sale
Aug 12, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 24, 2026
short_volume
Short Volume: CRL — 62.2% short (0.4M / 0.6M)
Short: 383,215 | Exempt: 0 | TRF Vol: 616,224 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: CRL — 56.4% short (0.4M / 0.7M)
Short: 372,835 | Exempt: 1 | TRF Vol: 661,433 | Short Ratio: 56.4% | Off-exchange volume (dark pool + OTC)
Sep 7, 2026
dark_pool
Dark Pool: CRL — 0.9M shares, 30,162 trades
Week starting 2026-09-07. Total ATS volume: 853,330 shares across 30,162 trades.
Aug 31, 2026
dark_pool
Dark Pool: CRL — 1.3M shares, 39,746 trades
Week starting 2026-08-31. Total ATS volume: 1,338,959 shares across 39,746 trades.
Aug 28, 2026
ftd
FTD: CRL — 2,147 shares ($0.6M) failed to deliver
Settlement: 20260828, Price: $296.41, FTD Value: $636,392.27, CHARLES RIVER LABS INT'L INC
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $2.96 | $2.92–$3.09 | 22.0% | +0.4% | 1↑ 9↓ | $1.0B | 12 |
| Next Q | $3.32 | $3.00–$3.46 | 38.8% | +0.1% | 9↑ 1↓ | $1.0B | 12 |
| Current FY | $11.35 | $11.02–$11.49 | 10.4% | +0.3% | 12↑ 1↓ | $3.9B | 17 |
| Next FY | $12.74 | $11.70–$13.68 | 12.2% | +0.4% | 13↑ 1↓ | $4.0B | 17 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $2.964 | — |
| 7d ago | $2.951 | +0.014 |
| 30d ago | $2.952 | +0.013 |
| 60d ago | $3.055 | -0.090 |
| 90d ago | $3.045 | -0.080 |
Institutional ownership
Which big funds own CRL (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $10.5B total value (46,518,387 shares) as of 2026-Q2. Top holders: FMR, BlackRock,, VANGUARD. Net buying activity: 35 institutions added/increased vs 15 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 4,239,752 | $961.5M | 9.1% | — |
| BlackRock, Inc. | 3,798,560 | $861.5M | 8.2% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,149,288 | $714.2M | 6.8% | — |
| Invesco Ltd. | 2,984,785 | $676.9M | 6.4% | — |
| HARRIS ASSOCIATES L P | 2,241,144 | $508.3M | 4.8% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,210,979 | $501.4M | 4.8% | — |
| Allspring Global Investments Holdings, LLC | 1,905,247 | $436.5M | 4.1% | — |
| STATE STREET CORP | 1,864,284 | $422.8M | 4.0% | — |
| DIMENSIONAL FUND ADVISORS LP | 1,648,450 | $373.8M | 3.5% | — |
| ARIEL INVESTMENTS, LLC | 1,506,185 | $341.6M | 3.2% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | ADD | 414,728 | 639,803 | +54.3% | $145.1M |
| MILLENNIUM MANAGEMENT LLC | TRIM | 934,045 | 486,462 | -47.9% | $110.3M |
| Amundi | TRIM | 773,315 | 412,402 | -46.7% | $93.5M |
| NORGES BANK | NEW | — | 370,040 | — | $83.9M |
| MARSHALL WACE, LLP | DOUBLED | 149,651 | 342,995 | +129.2% | $77.8M |
| CITIGROUP INC | DOUBLED | 81,311 | 316,217 | +288.9% | $71.7M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | TRIM | 737,030 | 278,558 | -62.2% | $63.2M |
| RAYMOND JAMES FINANCIAL INC | ADD | 193,532 | 256,779 | +32.7% | $58.2M |
| Alyeska Investment Group, L.P. | TRIM | 558,633 | 235,000 | -57.9% | $53.3M |
| LOOMIS SAYLES & CO L P | ADD | 170,982 | 223,668 | +30.8% | $50.7M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 50 transactions. Net -$42.6M — $0.00 bought, $42.6M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 25, 2026 | FOSTER JAMES C | Director | SELL | 33,561 | $300.00 | $10.1M |
| Aug 25, 2026 | FOSTER JAMES C | Director | EXERCISE | 21,132 | $194.12 | $4.1M |
| Aug 25, 2026 | FOSTER JAMES C | Director | EXERCISE | 12,429 | $208.44 | $2.6M |
| Aug 19, 2026 | Girshick Birgit | Chief Executive Officer | GIFT | 528 | — | — |
| Aug 19, 2026 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | EXERCISE | 2,039 | $194.12 | $395.8K |
| Aug 19, 2026 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | SELL | 2,039 | $294.12 | $599.7K |
| Aug 18, 2026 | Andrews Nancy C | Director | EXERCISE | 573 | $164.30 | $94.1K |
| Aug 18, 2026 | Andrews Nancy C | Director | SELL | 573 | $285.24 | $163.4K |
| Aug 11, 2026 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | EXERCISE | 3,714 | $179.66 | $667.3K |
| Aug 11, 2026 | Girshick Birgit | Chief Executive Officer | SELL | 6,500 | $279.90 | $1.8M |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CRL.
Shares short
2,230,517
Settlement Sep 15, 2026
Change vs prior
-12.0%
Semi-monthly cycle
Days to cover
2.8
At avg daily volume
Of shares outstanding
≈4.7%
Estimate — not % of float
All CRL filing & press-release reports (8)
- CLUSTER reportAug 28, 2026
- CLUSTER reportAug 21, 2026
- CLUSTER reportAug 14, 2026
- CLUSTER reportAug 12, 2026
- CLUSTER reportAug 11, 2026
- 8-K reportAug 5, 2026
- 8-K reportMay 7, 2026
- 8-K reportFeb 25, 2026